SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Wedbush Maintains Neutral on Karyopharm Therapeutics, Raises Price Target to $26

Wedbush maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Neutral and raises the price target from $25 to $26.

Benzinga · -
Wedbush maintains Karyopharm Therapeutics (NASDAQ: KPTI) with a Neutral and raises the price target from $25 to $26.